What is the maximum lifetime cumulative dose of doxorubicin for a patient receiving cyclophosphamide?

The maximum lifetime cumulative dose of doxorubicin is an important consideration in cancer treatment due to the risk of cardiotoxicity associated with the drug. Doxorubicin is an anthracycline antibiotic commonly used in chemotherapy regimens, and the cumulative dose should be carefully monitored to minimize heart-related side effects.

The correct maximum cumulative dose of doxorubicin for a patient receiving cyclophosphamide is 450 mg/m². This figure is based on established guidelines that aim to protect patients from the potential cardiotoxic effects of doxorubicin, especially when used in combination with other agents like cyclophosphamide, which can also have cardiovascular effects.

The cumulative limit of 450 mg/m² takes into account patient tolerance, the type of cancer being treated, and any previous treatment regimens. It is critical to manage these dosages to ensure patient safety while providing effective treatment. Monitoring the total lifetime exposure to doxorubicin helps healthcare providers to make informed decisions regarding chemotherapy, avoiding doses that may lead to irreversible cardiotoxicity in susceptible individuals.